Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...
SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...
Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced encouraging top-line results from an IST evaluating SER-155 in patients with ...
Once regarded as a disease affecting people over the age of 50, colorectal cancer is now rising at an alarming rate among ...
A quiet layer of biology is beginning to change how health is understood, and it sits on the surface of nearly every cell in ...
Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI. You are ...
DRB1*01:03 allele was associated with severe outcomes across inflammatory bowel disease subtypes, including perianal complications, advanced therapy use and surgical interventions, according to study ...
The Rome V criteria for IBS identified a different group of patients, with lower sensitivity than either Rome III or IV ...
Evommune, Inc.’s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN’s pipeline because the same biology now needs cleaner data in AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results